Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can
prevent immune related adverse events in participants with stage III-IV melanoma that cannot
be removed by surgery who are undergoing nivolumab and ipilimumab therapy.